FDA's Decentralized Clinical Trial Framework: An Audit Readiness Guide for 2026

FDA released its final decentralized clinical trial guidance in May 2023 — and nearly three years later, the gap between what sponsors think it requires and what FDA inspectors actually expect during a BIMO (Bioresearch Monitoring Program) audit remains wider than most would like to admit.

Decentralized clinical trials (DCTs) — studies that use remote technologies to conduct some or all trial activities outside a traditional clinical site — have grown sharply since 2020. By 2025, an estimated 60% of Phase II and Phase III drug trials incorporated at least one decentralized element: eConsent, remote patient monitoring, direct-to-participant (DTP) drug shipment, or telemedicine visits. The technology adoption has accelerated far faster than the compliance infrastructure supporting it.

That’s where inspectional findings pile up.

What FDA’s 2023 DCT Guidance Actually Changed (and What It Didn’t)

The May 2023 guidance didn’t create new regulations. It interpreted existing ones — 21 CFR Part 312 (IND requirements), 21 CFR Part 50 (informed consent), 21 CFR Part 56 (IRB oversight), and 21 CFR Part 11 (electronic records and signatures) — through the lens of decentralized trial operations. That distinction matters enormously when you’re preparing a Form FDA 483 response.

FDA’s core position is that DCTs must meet the same regulatory standards as traditional site-based trials. The technology changes the delivery mechanism; it doesn’t change the obligation. Sponsors who’ve built their DCT SOPs around the idea that remote operations get more operational flexibility consistently find themselves in trouble.

A few specific expectations the guidance made explicit:

Sponsor oversight of local healthcare providers (LHPs) doesn’t end because activities happen at the patient’s home. Sponsors must ensure LHPs understand their protocol obligations and are appropriately qualified — with documentation to prove it.

Remote informed consent via electronic means must satisfy all requirements under 21 CFR 50.25, including a genuine opportunity for participants to ask questions and a mechanism for the IRB to review and approve the eConsent process, not just the consent document.

Data integrity from wearables and remote monitoring devices must be addressed in the protocol with written data management procedures. FDA explicitly flagged that automatic data capture from connected devices doesn’t, by itself, satisfy the requirement for human oversight of data quality.

What the guidance didn’t change: the primary accountability structure. The sponsor remains responsible under 21 CFR 312.50 for ensuring the trial is conducted in accordance with the protocol. Distributing activities across LHPs, CROs, and technology vendors doesn’t distribute that accountability.

The Five Areas FDA Inspectors Focus On During DCT Audits

BIMO inspectors conducting clinical investigator or sponsor audits of DCTs cluster their observations around five functional areas. Understanding these patterns is the foundation of any solid inspection readiness posture — and the starting point for any serious regulatory compliance consulting engagement in this space.

1. Delegation of Authority and Vendor Oversight

In conventional trials, the delegation of authority (DOA) log maps each activity to a qualified, trained individual at the site. In DCTs, that mapping gets complicated fast. Who is authorized to conduct telemedicine visits? Who receives and records wearable device data? If a home health nurse draws blood, are they on the DOA log, and has their training been documented?

FDA has issued warning letters citing failure to maintain adequate oversight of vendors and LHPs. A 2024 warning letter to a mid-size oncology sponsor specifically cited “inadequate documentation of oversight activities for remote clinical staff not directly employed by the clinical site.” The sponsor had the SOPs. They didn’t have the records proving the SOPs were followed.

2. eConsent Process Integrity

The consent form is the easy part. The process is where inspections find problems. FDA looks for evidence that the IRB-approved consent process — not just the document — was followed; that participants had a genuine opportunity to ask questions before signing, with documentation of that interaction; that re-consent procedures were triggered when protocol amendments required them; and that the audit trail in the eConsent system meets 21 CFR Part 11 requirements (timestamped, user-attributed, non-repudiable).

In a 2024 inspection of a Phase III cardiovascular trial, inspectors found that the eConsent platform’s audit log recorded the timestamp of the electronic signature but not the sequence of screens viewed or the duration of the consent session. The sponsor had assumed the platform was Part 11-compliant. The vendor’s validation documentation told a different story.

3. Direct-to-Participant Drug Shipment Controls

DTP shipment is operationally attractive but creates a chain-of-custody problem that FDA takes seriously. Sponsors must demonstrate control over drug accountability at every node — including the patient’s home. That means temperature monitoring during transit, documented receipt confirmation from participants, and pre-approved procedures for handling missed doses, participant withdrawals, and drug return or destruction.

The most common 483 observation in this area isn’t missing data — it’s the absence of a pre-approved procedure. Sponsors that stand up DTP shipment without explicit protocol language and without prospective IRB review of the home drug handling process consistently generate inspection findings.

4. Protocol Deviation Management

DCTs generate more protocol deviations than site-based trials. Participants miss virtual visits. Devices malfunction. Shipments are delayed. The question FDA asks isn’t whether deviations occurred — they always do — but whether the sponsor’s deviation management system detected them in real time and applied appropriate corrective action.

Expect FDA inspectors to pull the deviation log and cross-reference it against source data from remote monitoring platforms. Gaps of 30 to 60 days between a detectable event and a logged deviation represent a significant audit risk. That gap tells an inspector the system wasn’t monitoring proactively; it was documenting reactively.

5. Electronic Records and 21 CFR Part 11 Compliance

DCTs run almost entirely on electronic systems — eCOA platforms, eConsent tools, remote monitoring dashboards, central laboratory portals. Every system that creates, modifies, maintains, archives, retrieves, or transmits records required by FDA is subject to Part 11.

The most persistent finding in this category is failure to validate third-party platforms. “The vendor told us it was compliant” is not a defense that survives a BIMO inspection. Sponsors must obtain and critically review vendor validation documentation, confirm it covers the specific software version in use, and address any gaps through their own supplemental validation activities.

Building an Audit-Ready DCT Documentation Architecture

An audit-ready DCT program isn’t just about having the right SOPs on paper. It’s about being able to demonstrate — with records — that those SOPs were followed prospectively, not reconstructed after the inspection visit was announced. Here’s what that documentation architecture should include.

Technology Qualification Package: For each DCT-enabling technology (eConsent, eCOA, wearables, telemedicine platform), maintain a vendor qualification package that includes the vendor’s validation documentation, your own user acceptance testing records, and a gap analysis against 21 CFR Part 11 requirements. This package must be updated whenever the vendor releases a material software update.

LHP Training Records: Every local healthcare provider conducting protocol-specified activities needs documented training on the protocol, applicable SOPs, and adverse event reporting procedures — completed before they interact with any participant. This sounds basic. It’s one of the most frequently cited gaps in DCT inspections.

DCT-Specific Monitoring Plan: Your overall monitoring plan should include a dedicated DCT section addressing how remote source data verification will be conducted, at what frequency, and by whom. FDA inspectors will pull monitoring visit reports and look for evidence that risk signals from remote monitoring data were escalated appropriately and promptly.

IRB Communication Log: Maintain a chronological log of all IRB submissions and approvals related to the DCT elements — including amendments triggered by protocol deviations, technology changes, or consent process updates. IRB approval of the consent document is necessary but not sufficient; IRBs must also approve the consent process, including the specific technology platform used to deliver it.

Deviation Trending Analysis: Log deviations — but also analyze them. FDA increasingly expects sponsors to demonstrate that their CAPA system responds to deviation trends, not just individual events. A quarterly deviation trending report, reviewed by a designated quality function and retained in the trial master file, creates exactly that evidence trail. It’s also one of the first documents an inspector will request.

What Happens When Gaps Are Found

FDA’s enforcement response to DCT compliance failures escalated sharply between 2024 and 2025. Prior to 2024, most DCT-related inspectional findings were resolved through 483 responses and commitment letters. In 2025, FDA placed two sponsors on clinical hold specifically citing inadequate oversight of decentralized elements — a clear signal that the agency is prepared to use its sharpest enforcement tools in this space.

The pattern in both clinical holds was similar: not a single catastrophic failure, but a constellation of documentation gaps that collectively demonstrated the sponsor lacked adequate oversight of the trial’s decentralized components. Individually, each finding might have been addressable. Together, they painted a picture of a compliance infrastructure that wasn’t built for DCT operations.

The ICH E6(R3) GCP guideline — finalized in 2023 and now the global benchmark for clinical trial conduct — reinforces FDA’s position. Its risk-based quality management principles require sponsors to identify and mitigate quality risks before they become protocol deviations or data integrity failures. For DCTs, that means front-loading the compliance work: qualifying vendors, training LHPs, and validating data flows before the first participant is enrolled, not after the first inspection observation is issued.

If your organization is running a DCT and hasn’t conducted an internal mock inspection against FDA’s 2023 guidance and ICH E6(R3), that’s the first item on the list. The BIMO inspection will come — the question is whether your records tell a coherent story of prospective oversight, or a scrambled story of reactive documentation.

Build the system before the inspector arrives. Everything else is harder.

Written by Sam Sammane, Founder & CEO, Aurora TIC. Learn more about our team

Talk to our compliance consultants Contact us

Related from our network

• ISO 17025-Accredited Analytical Testing for Clinical Trial Samples — Third-party laboratory testing to support IND data packages and clinical trial data integrity requirements.
• GMP-Compliant Drug Testing for Canadian Clinical Studies — Health Canada-aligned analytical testing for Phase I–III investigational drug materials.